1. In Vivo

A Steady Year For The Top Tier In Pharma Ahead Of Major Upheaval

 
• By Jessica Merrill

Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.

IV1912_Scrip-100_Upheaval_572140570_1200.jpg
Change on the horizon for big pharma • Source: Shutterstock

It was generally a steady year in the top pharmaceutical companies, based on full year 2018 pharma sales. There were notable fluctuations, but nothing like what will be in store for the industry if the big deals and M&A that have been announced in 2019 move forward as anticipated. The industry is poised for a major reshaping in the years ahead.

One of the big movers in the Scrip 100 top 10 rankings this year was Bristol-Myers Squibb Co., which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.